[{"orgOrder":0,"company":"Biddle Sawyer Corporation","sponsor":"TAE Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"TC220","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biddle Sawyer Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biddle Sawyer Corporation \/ TAE Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Biddle Sawyer Corporation \/ TAE Life Sciences"}]

Find Clinical Drug Pipeline Developments & Deals for TC-220

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the agreement, Biddle will serve as the exclusive supplier of TC220, a proprietary boronated amino acid analog developed by TAE Life Sciences to support BNCT cancer treatment.

                          Brand Name : TC220

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 15, 2023

                          Lead Product(s) : TC-220

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : TAE Life Sciences

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank